09995 REMEGEN
- 30.000
- +2.050+7.33%
REMEGEN News
[Broker Focus] Zhongtai Securities first gave Rongchang Biotech (09995) a “buy” rating indicating that it has the ability to complete the entire chain from R&D to commercialization
Jinwu Financial News | According to the Zhongtai Securities Research Report, Rongchang Biotech (09995), as a pioneer in self-immunization+ cancer in China, has the ability to complete the entire chain of R&D to commercialization, and is promoting many clinical studies overseas. Two products have been marketed, and impressive data have been found in multiple clinical studies. According to the bank, verdicitumab is a HER2ADC that was approved for marketing earlier. It is promoting clinical research on new indications for different segments of the population in the fields of dominant gastric cancer and urothelial cancer. The bank believes that the revenue of verdicitril in 2024-2026 was 7.6/8.5/1.17 billion yuan, respectively. Tetracip as SLE's
Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan
Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.
Great Week for RemeGen Co., Ltd. (HKG:9995) Institutional Investors After Losing 33% Over the Previous Year
Key Insights Given the large stake in the stock by institutions, RemeGen's stock price might be vulnerable to their trading decisions The top 8 shareholders own 51% of the company 12% of RemeGen
榮昌生物：2024年第一季度報告
Rongchang Biotech (688331.SH) announced first-quarter results with a net loss of 349 million yuan
Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...
榮昌生物：2023 年度報告
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 4%, and the company plans to increase nearly 2.6 billion yuan. The agency says there are many catalysts this year
Rongchang Biotech (09995) rose more than 4%. As of press release, it rose 4.76% to HK$29.7, with a turnover of HK$126.792 million.
Lu Tai A (000726.SZ): Currently holds about 3.91 million shares of Rongchang Biotech, and there are no plans to reduce its holdings
Gelonghui, April 17 | Lu Tai A (000726.SZ) said on the investor interactive platform that the company currently holds about 3.91 million shares of Rongchang Biotech and has no plans to reduce its holdings. The fund jointly set up by the company and Haojun Investment has an investment of about 50 million yuan.
Rongchang Biotech (09995.HK) plans to hold a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16, 丨 Rongchang Biotech (09995.HK) announced that the company will hold a board meeting on April 26, 2024 (Friday) to consider and approve (among other things) the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their publication.
榮昌生物：董事會召開日期
How many difficulties are there on the way to the Rongchang Biotech Plan's fixed increase of over 2 billion yuan
“Investor Network” Cai Jun Rongchang Biotech (688331.sh, hereinafter referred to as the “Company”) has reached another critical point. At the end of March, the company announced a fixed increase plan. It plans to raise up to 2.55 billion yuan, all of which will be used for “new drug research and development projects”, including RC18, RC48, RC28, RC88, RC148, and RC198. Around the same time, the company also released its 2023 annual report. Up to now, the company's core marketed products include taitacip, verdicitumab, etc. During the reporting period, the company's revenue increased by 40.26% year on year, net profit to mother - 1.51 billion yuan, loss
CCB International: Maintaining Rongchang Biotech's (09995) “Outperform the Market” rating and raising the target price to HK$34
CCB International expanded the adjusted net loss forecast for Rongchang Biotech (09995) in 2024 from a loss of 1.3 billion yuan to a loss of 1.4 billion yuan.
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 9% in the afternoon, rapid release of core products, and the company has many catalysts this year
Rongchang Biotech (09995) rose more than 9% in the afternoon. As of press release, it was up 7.9% to HK$33.45, with a turnover of HK$68.303 million.
[Broker Focus] CITIC Construction Investment cuts Rongchang Biotech's (09995) target price to HK$41.66 to maintain a “buy” rating
Jinwu Financial News | According to CITIC Construction Investment Research Report, Rongchang Biotech (09995) achieved revenue of 1,083 billion yuan in 2023, an increase of 40.26% over the same period last year, and achieved strong growth on the revenue side. In 2024, the company has many catalysts. Overseas SLE3 clinical phase I data of titacipu is expected to be read. At the same time, overseas back-line UC indications for verdicitumab are expected to be completed and submitted for marketing. The bank believes that as the company's commercialization team becomes more mature, the company's two core products will see significant increases in sales and cost control, and sales of both products are expected to be in 2024
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ramsay Health Care (OtherRMSYF), Glass House Brands (OtherGLASF) and RemeGen Co. Ltd. Class H (HK:9995)
Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication
The US Food and Drug Administration granted fast-track designation to Remegen's (HKG:9995) Telitacicept medication for the treatment of primary Sjögren's syndrome, according to a Tuesday filing with
RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD)...
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose nearly 5%, Taitaxip received FDA Fast Track certification, and the company plans to raise more than 2.5 billion dollars in A-shares
The Zhitong Finance App learned that Rongchang Biotech (09995) rose nearly 5% in early trading. As of press release, it had risen 4.16% to HK$28.8, with a turnover of HK$21.9629 million. According to the news, Rongchang Biotech announced that the US Food and Drug Administration (FDA) granted Taitacip (RC18, trade name: Taiai) fast track qualification for the treatment of patients with primary dry syndrome (PSs). At the end of 2023, the FDA approved the Phase III New Drug Clinical Study (IND) application for titacipr to treat patients with pSS. Furthermore, Rongchang Biotech announced that the board of directors passed the decision
Analysis
Price Target
No Data
